Aerosol Science

Dose Uniformity & Emitted Dose Testing

Dose output and uniformity for inhalers, nebulizers, and nasal sprays, with collection and endpoints selected for the device and protocol.

We use compendial collection trains, controlled flow and actuation, and HPLC / ELISA / qPCR-ddPCR quantitation to document emitted dose, dose uniformity, and contributors to variability for each study.

ISO 17025USP <601>USP <1601>FDA MDI / DPI / nasalReviewed 2026-10-20
Request a quoteSubmit a sample

Purpose & when to use

Dose Uniformity and Emitted Dose (DU / ED) testing measures active or tracer reaching a defined collection point. The device and protocol determine whether endpoints are per actuation or timed delivery. Compendial collection trains, controlled flow and actuation, and HPLC / ELISA / qPCR-ddPCR quantitation provide device-specific dose and variability metrics. USP <601> and FDA guidance apply to relevant inhaler or nasal endpoints; USP <1601> addresses nebulized pulmonary products. Uses include:

  1. USP <601> and FDA guidance inform inhaler or nasal dose studies; USP <1601> nebulization endpoints include delivery rate and total delivered drug. Per-actuation endpoints depend on device and protocol.
  2. In vitro bioequivalence and comparability packages for predicate and lifecycle changes — dose-uniformity trending and statistical equivalence framing under FDA bioequivalence and ICH Q5E guidance.
  3. Formulation and component-tolerance screening during development — fast shot-to-shot dose checks for valve, pump, nozzle, or excipient changes under FDA development-stage CMC guidance.
  4. Drift investigation across fill level, aging, storage conditions, and device wear — supports stability and shelf-life packages under USP <601> and ICH Q1A framing.
  5. Variability root-cause investigation when emitted dose exceeds spec — pairs with PSD and high-speed imaging under ICH Q9 quality-risk framing to isolate actuation, leakage, or component contributors.

Use DU / ED testing when emitted dose or uniformity drives a regulatory or commercial question, including submission packages, predicate comparisons, stability programs, or formulation iteration. The data tie dose measurements to controlled actuation, flow, and collection, with documentation for inspection.

Built for inhalation, intranasal, and oral drug delivery

DU / ED testing spans the device classes where per-actuation dose is the central performance attribute — pharmaceutical inhalation and intranasal devices plus oral spray products under a documented quality system.

  • MDIMetered-dose inhalers
  • DPIDry-powder inhalers
  • NebulizerLiquid aerosol generators
  • Nasal sprayIntranasal delivery
  • Oral spraySublingual and topical-oral

Instrumentation & measurement ranges

We select the platform for the device class, the active, and the regulatory framework. Each component is defined during study planning and documented in the report.

1 – 100 L/mininduction-port-flow

Compendial collection trains (USP-aligned fixtures)

USP-aligned induction port, mouthpiece adapters, and nasal / oral interfaces — compliant geometry for emitted-dose collection across MDI, DPI, nebulizer, and nasal-spray devices.

1 – 100 L/mincontrolled-flow

Mass-flow controllers and inhalation profile rigs

Calibrated flow control for steady-state and breathing-simulation profiles — pinned by mass-flow controllers and logged shot-by-shot for traceable per-actuation conditions.

0.1 – 100 Nactuation-force

Stepper-driven actuation fixtures

Controlled stroke, force, and timing under stepper control — manual, pneumatic, or mechanical fixtures sized to mimic patient or operator use across the actuation envelope.

0.1 – 1000 µgper-actuation

Analytical quantitation suite (HPLC, ELISA, qPCR / ddPCR)

HPLC for small-molecule actives, ELISA for protein analytes, and qPCR / ddPCR for nucleic-acid actives — assay matched to the active and matrix on a per-study basis.

Test method options

MethodStrengthsTradeoffAligned with
Compendial-aligned emitted dose and uniformity (USP <601> / <1601>)
  • USP <601> collection conditions are selected for the inhaler or nasal endpoint.
  • USP <1601> nebulization endpoints include delivery rate and total delivered drug; per-actuation measures depend on the device and protocol.
Strict fixture, flow, and assay control overhead — best when the device is locked and the data is filing-bound.
USP <601>USP <1601>FDA MDI / DPI / nasal
Development screening for dose consistency
  • Faster iteration with reduced replicates — supports formulation, valve, pump, and component-tolerance screening under FDA development-stage CMC framing.
  • Same fixtures as the compendial method but acceptance bands tuned for iteration speed over filing rigor — design-team-friendly cadence.
May require follow-on confirmation under compendial conditions before filing — bridge to the regulator-aligned method when the program approaches submission.
FDA MDI / DPI / nasal
Robustness study (actuation profile, flow, environment)
  • Surfaces sensitivity to actuation force, flow profile, fill level, and temperature — defines the use-condition envelope where dose stays in spec.
  • Output feeds change-control packages and predicate comparisons under USP <601> and FDA MDI / DPI / nasal change-control framing.
More conditions per study increase sample count and analyst time — scope tightly to the variables that drive the decision.
USP <601>FDA MDI / DPI / nasal
Troubleshooting and root-cause investigation
  • Pinpoints sources of variability — valve, pump, viscosity, leakage, or actuator wear — using paired methods and instrument records.
  • Often paired with PSD or plume geometry under ICH Q9 quality-risk framing so the investigation closes with a defensible CAPA package.
Iterative by nature — schedule unpredictability is higher than fixed-protocol studies; budget for two or three investigation rounds.
ICH Q9

Setup configurations

Controlled flow, actuation, and traceable collection are central to each DU / ED setup. We configure the study for the device, the active, and the regulatory framework, balancing compendial rigor with the practical requirements of the device under test. The parameters below are set during study planning:

Device interfaces

Mouthpiece adapters, induction ports, nasal and oral interfaces — geometry matched to the device class and the compendial frame under test.

Flow & actuation profiles

Mass-flow-controlled flow profiles, stepper-driven actuation force and stroke, and defined shot schedules — every parameter logged shot-by-shot.

Sample numbers

Replicates per device and across devices — power sized to declared shot-to-shot and device-to-device variability with documented statistical framing.

Media & handling

Collection-media selection, extraction-solvent compatibility, and documented storage for collected fractions and analytical samples.

Calibration & verification

Mass-flow controllers, actuation force, and assay calibration verified against traceable standards before each campaign and between condition blocks.

Methods anchored to the standards that matter

Every DU / ED study follows a documented quality system aligned with the regulatory frameworks for inhalation, intranasal, and oral-spray products. The references below guide study controls, records, and reporting.

  • ISO 17025AccreditedTesting-laboratory competence — documented methods, calibration traceability, and uncertainty contributors.
  • USP <601>AccreditedAerosols, nasal sprays, MDIs, and DPIs — performance quality tests including delivered-dose uniformity.
  • USP <1601>AlignedProducts for nebulization — characterization tests including aerosol output and dose.
  • FDA MDI / DPI / nasalAlignedChemistry, manufacturing, and controls plus bioequivalence framing for inhalation and intranasal submissions.

Key data outputs & reporting

Each DU / ED report includes the selected dose endpoint, uniformity statistics where applicable, and supporting datasets: emitted dose per shot, summary statistics (mean, SD, CV), and dose-vs-shot trending where applicable. Traceable QA / QC controls accompany the results. Reports are formatted for submission packages, change-control documentation, or development decisions. The table lists standard deliverables; extended artifacts for comparability programs, predicate studies, and stability time-courses follow below.

Primary outputs

  • Emitted dose per actuation, or nebulization delivery rate and total delivered drug, with device-specific summary statistics (mean, SD, CV).
  • Dose-uniformity trending across shot number, fill level, or canister-life position with predefined acceptance bands.
  • Assay calibration, recovery, and uncertainty contributors documented alongside results for inspection-readiness.

Deliverables

#FormatContents
01PDF reportMethods, controls, statistical framing, and acceptance logic.
02CSV / XLSX datasetsPer-shot dose, replicate statistics, and condition deltas.
03FiguresDose-vs-shot plots, condition overlays, and distribution charts for internal review and submission appendices.
Extended deliverables · multi-arm comparability · stability · predicate studies
  • Comparability appendix — Side-by-side dose-vs-shot overlays plus statistical equivalence tests per ICH Q1E or product-specific predicate framing.
  • Stability time-course pack — Emitted-dose and uniformity trends across timepoints with predefined OOT criteria flagged per ICH Q1A.
  • Method-development notes — Fixture, actuation, and assay-selection rationale plus uncertainty contributors — for submission cover letters and inspection readiness.

QA / QC & data integrity

Each DU / ED study includes documented QA / QC controls and verifications matched to the method plan, regulatory framework, analytical chemistry, and decision the data will support. The checks below run alongside dose collection and are audited under our ISO 17025 quality system, with traceability from sample receipt through the final result. We add recovery, system suitability, and matrix-effect checks when the assay requires them.

Blanks and background controls for collection media plus fixture-residue checks before each campaign.

Replicate measurements and repeat runs to quantify shot-to-shot and device-to-device precision.

Assay controls — calibration standards, system suitability per assay, and spike-recovery on matrix-challenging analytes.

Flow and actuation verification logs alongside captured doses with mass-flow controller calibration records.

Chain of custody from sample receipt through analysis and final reporting.

RESEARCH / THIS WORK IN PRACTICE

Real studies. Measured evidence.

Explore published studies connected to dose uniformity and emitted dose. Each explains the study question, approach and findings.

View related studies (1)
Inhalation & Drug Delivery

Dry-Powder Nasal Spray Testing: Phase 1 Characterization

The study established an early performance baseline for comparing the two variants and provided data for a regulatory-facing Phase 1 characterization package. It did not assess clinical efficacy or support claims of approval.

Selected finding
Recovered material was predominantly classified in the nasal or upper-airway region for both variants.
Nasal deliveryParticle sizingDevice evaluation

Study-specific findings do not guarantee performance for another product.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)
17025Accredited testing
900+Studies Performed
17+Years in operation
300+Clients supported

Common questions

The questions below address assay selection, fixture choice, replicate plans, comparability framing, and deliverables for inhalation, intranasal, and oral-spray teams planning dose uniformity or emitted dose testing. These answers are starting points, not protocols. Most DU / ED studies need at least one custom configuration choice; contact us if your device, active, or regulatory framework differs from those described here.

Q.Is emitted dose the same as delivered dose?
A.Emitted dose is what we collect at the device outlet through a defined compendial fixture. Delivered dose can require additional anatomical models, breathing simulations, or in vivo work. We define the collection point during study planning.
Q.Can you quantify biologics or nucleic-acid actives?
A.Yes. We use ELISA for protein analytes and qPCR / ddPCR for nucleic-acid actives. Assay controls, system suitability, and recovery are documented alongside the results. The compendial fixtures stay the same; the assay is matched to the active.
Q.How many actuations should be tested?
A.It depends on device output, assay sensitivity, and the comparability target. Submission packages typically use n=10+ devices with replicates across canister positions; development screening uses a smaller sample plan. We set shot counts during study planning.
Q.What drives dose variability most often?
A.Common contributors include actuation force and timing, component tolerances (valve, pump, nozzle), leakage, and formulation viscosity. We control flow and actuation, log each shot, and document assay recovery so the comparison remains interpretable.
Q.What do you deliver?
A.Deliverables include a PDF report with methods, controls, statistical framing, and acceptance logic, plus CSV / XLSX datasets for per-shot dose and replicate statistics. Figures show dose-vs-shot trends, condition overlays, and distributions for internal review and submission appendices.

Standards & guidance

ARE Labs aligns DU / ED studies with the regulatory and consensus standards relevant to inhalation, intranasal, and oral-spray dose delivery. We identify methods as accredited only where we hold third-party accreditation for that scope (ISO 17025, USP <601>). When we follow a standard without formal accreditation, we describe the method as aligned or conformant where applicable. The cards below list the standards most often relevant to DU / ED packages.

Inhalation & Drug Delivery - Accredited

USP <601>

Aerosols, nasal sprays, MDIs, and DPIs — performance quality tests including delivered-dose uniformityView standard ->Inhalation & Drug Delivery - Aligned

USP <1601>

Products for nebulization — characterization tests including aerosol output and doseView standard ->QA & Regulatory - Aligned

FDA MDI / DPI / nasal

Chemistry, manufacturing, controls, and bioequivalence framing for inhalation and intranasal submissionsView standard ->QA & Regulatory - Aligned

ICH Q9

Quality risk management — investigation framing for dose-variability root-cause workView standard ->

Related services & devices

Service

Particle Size Distribution (PSD) Testing

Pairs with DU / ED for inhalation submissions — size-fraction data complementing per-actuation dose for the full performance package.Read more ->Devices

Respiratory Drug Delivery Devices

MDI, DPI, and nebulizer programs — emitted dose, uniformity, and submission-grade characterization across the device portfolio.Read more ->Service

Spray Pattern & Plume Geometry

Pairs with DU / ED for nasal-spray submissions — plume metrics that contextualize per-actuation dose against device geometry.Read more ->Devices

Intranasal Delivery Devices

Nasal pumps, multi-dose sprays, and unit-dose devices — per-actuation dose plus comparability characterization for nasal submissions.Read more ->